2022
DOI: 10.1016/s2213-8587(22)00045-6
|View full text |Cite
|
Sign up to set email alerts
|

Levothyroxine in euthyroid thyroid peroxidase antibody positive women with recurrent pregnancy loss (T4LIFE trial): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
32
1
2

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 55 publications
(36 citation statements)
references
References 23 publications
1
32
1
2
Order By: Relevance
“…It remains difficult to determine whether levothyroxine treatment is of benefit in TPOAb positive women during pregnancy. We have now learned from three well-performed randomized trial that there is no benefit of preconception levothyroxine treatment for euthyroid TPOAb positive women [25][26][27]. However, the randomized trial data for gestational levothyroxine treatment of euthyroid TPOAb positivity are poor since there are no randomized trials focusing primarily on euthyroid TPOAb positivity but only subanalyses can be identified.…”
Section: Levothyroxine Treatmentmentioning
confidence: 99%
“…It remains difficult to determine whether levothyroxine treatment is of benefit in TPOAb positive women during pregnancy. We have now learned from three well-performed randomized trial that there is no benefit of preconception levothyroxine treatment for euthyroid TPOAb positive women [25][26][27]. However, the randomized trial data for gestational levothyroxine treatment of euthyroid TPOAb positivity are poor since there are no randomized trials focusing primarily on euthyroid TPOAb positivity but only subanalyses can be identified.…”
Section: Levothyroxine Treatmentmentioning
confidence: 99%
“…In conclusion, an effective treatment to prevent them is still unavailable, although evidence has suggested that euthyroid females with AIT have a high risk of experiencing adverse obstetric outcomes. This was further confirmed by the recent T4LIFE trial, which showed that LT4 administration did not result in higher live birth rates in patients with AIT with euthyroidism with recurrent pregnancy loss [ 88 ], thus leading to research on other treatment strategies.…”
Section: Autoimmune Thyroiditis In Pregnancymentioning
confidence: 74%
“…The ATA also proposed considering levothyroxine for women with thyroid autoimmunity and TSH above 2.5 mIU/L and for euthyroid infertile women with a history of pregnancy loss. After the publication of the ATA guidelines, several important randomized clinical trials (RCTs) were released, which makes it necessary to reconsider this perspective ( Table 1 ) ( 84 90 ). Moreover, four meta-analyses including only RCTs could not find any evidence that levothyroxine supplementation in euthyroid women with AITD resulted in an improvement in maternal pregnancy outcomes ( 94 97 ).…”
Section: Treatment Optionsmentioning
confidence: 99%
“…The results of the meta-analyses have also shown that initiating levothyroxine during the preconception period or in the first trimester did not affect the miscarriage risk. Finally, the highly anticipated T4-LIFE trial addressing the impact of levothyroxine treatment in TPOAb-positive euthyroid women with recurrent miscarriage was published, and the levothyroxine intervention failed again to decrease the risk of pregnancy loss ( 90 ). Although these observations require further analysis, the only beneficial effect of levothyroxine treatment in TAI women documented so far is prevention of hypothyroidism.…”
Section: Treatment Optionsmentioning
confidence: 99%